Skip to main content

Advertisement

SpringerLink
Log in

Drug action against intracellularly growingMycobacterium xenopi

  • Published:
Current Microbiology Aims and scope Submit manuscript

Abstract

The intracellular growth kinetics ofMycobacterium xenopi was studied in the murine J-774 macrophage cell line model. During the initial 4 days of infection, the bacilli divided about every 33 h. Electron microscopy of infected macrophages showed that bacteria inside phagosomes were surrounded by a protective electron-transparent zone (ETZ). This model was used for comparing the extracellular and intracellular activities of the following drugs: pristinamycin (PRISTINA), isoniazid (INH), clofazimine (CLOFA), rifabutin (=ansamycin; ANSA), rifampicine (RIFA), streptomycin (SM), ethambutol (EMB), and five fluoroquinolones, namely, ciprofloxacin (CIPRO), ofloxacin (OFLO), pefloxacin (PEFLO), enoxacin (ENOX) and norfloxacin (NORFLO). All the drugs were tested within their obtainable serum level concentrations in man. Under these conditions, CLOFA, SM, CIPRO, and OFLO were highly active against intracellularly growingM. xenopi, INH and RIFA were moderately active, whereas ANSA, PRISTINA, EMB, PEFLO, ENOX, and NORFLO were only growth inhibiting. The comparison of these data with extracellular activities of the same drugs underlined the discrepancies observed in test-tube drug activity evaluation and its correlation with results of chemotherapy in patients in whom the drug has essentially an intracellular bacterial killing role.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literature Cited

  1. Bank J, Hunter AM, Campbell JA, Jenkins PA, Smith AP (1984) Pulmonary infection withMycobacterium xenopi: review of treatment and response. Thorax 39:376–382

    PubMed  Google Scholar 

  2. Beck A, Stanford JL (1968)Mycobacterium xenopi: a study of sixteen strains. Tubercle 49:226–234

    Google Scholar 

  3. Bullin CH, Tanner EI, Collins CH (1970) The isolation ofMycobacterium xenopi from water taps. J Hyg (Camb) 68:97–100

    Google Scholar 

  4. Contreras MA, Cheung OT, Sanders DE, Goldstein RS (1988) Pulmonary infection with nontuberculous mycobacteria. Am Rev Resp Dis 137:149–152

    PubMed  Google Scholar 

  5. Costrini AM, Mahler DA, Gross WM, Hawkins JE, Yesner R, D'Esopo ND (1981) Clinical and roentgenographic features of nosocomial pulmonary disease due toMycobacterium xenopi. Am Rev Resp Dis 123:104–109

    PubMed  Google Scholar 

  6. Damsker B, Bottone EJ, Deligdisch L (1982)Mycobacterium xenopi infection in an immunocompromised host. Human Pathol 13:866–870

    Google Scholar 

  7. DesBordes-Lize J, Fouye G, Lelieur G (1970) Contribution à l'étude deMycobacterium xenopi à l'occasion d'une importante endémie hospitalière. Poumon Coeur 26:1141–1182

    PubMed  Google Scholar 

  8. Elston HR, Duffy JP (1973)Mycobacterium xenopi and mycobacteriosis: a clinical and bacteriologic report. Am Rev Resp Dis 108:944–949

    PubMed  Google Scholar 

  9. Eng RH, Forrester C, Smith SM, Sobel, H (1984)Mycobacterium xenopi infection in a patient with acquired immunodeficiency syndrome. Chest 86:145–147

    PubMed  Google Scholar 

  10. Engbaek HC, Vergmann B, Baess I, Will DW (1967)Mycobacterium xenopi: a bacteriological study ofM. xenopi including case reports of Danish patients. Acta Pathol Microbiol Scand 69:576–594

    Google Scholar 

  11. Good RC, Snider DE (1982) Isolation of nontuberculous mycobacteria in the United States in 1980. J Infect Dis 146:829–833

    PubMed  Google Scholar 

  12. Gross WM, Hawkins, JE, Murphy DB (1976) Origin and significance ofMycobacterium xenopi in clinical specimens. I. Water as a source of contamination. Bull Int Union Tuberc 51:267–269

    PubMed  Google Scholar 

  13. Horak Z, Polakova H, Kralova M (1986) Water-borneMycobacterium xenopi: a possible cause of pulmonary tuberculosis in man. J Hyg (Praha) 30:405–409

    Google Scholar 

  14. Lemercier JP, Morel A, Savigny G, Thièrry C, Lambert J (1979) Étude de 960 souche deMycobacterium xenopi isolées en Seine-Maritime pendant 12 années. Rev Franç Mal Resp 7:510–512

    Google Scholar 

  15. Marks J, Schwabacher H (1965) Infection due toMycobacterium xenopi. Br Med J 1:32–33

    Google Scholar 

  16. McClatchy JK (1980) Antituberculous drugs: mechanisms of action, drug-resistance, susceptibility-testing, and assays of activity in biological fluids, In: Lorian V (ed), Antibiotics in laboratory medicine. Baltimore: William and Wilkins, pp 135–169

    Google Scholar 

  17. McSwiggan DA, Collins CH (1974) The isolation ofMycobacterium kansasii andM. xenopi from water systems. Tubercle 55:291–297

    PubMed  Google Scholar 

  18. Rastogi N, Fréhel C, David HL (1986) Triple-layered structure of mycobacterial cell wall: evidence for the existence of a polysaccharide-rich outer layer in 18 mycobacterial species. Curr Microbiol 13:237–242

    Google Scholar 

  19. Rastogi N, Potar MC, David HL (1987) Intracellular growth of pathogenic mycobacteria in the continuous murine macrophage cell line J-774: ultrastructure and drug-susceptibility studies. Curr Microbiol 16:79–92

    Google Scholar 

  20. Rastogi N, Goh KS, David HL (1988) Activity of five fluoroquinolones againstMycobacterium avium-intracellulare complex andM. xenopi. Ann Inst Pasteur/Microbiol 139:233–237

    Google Scholar 

  21. Simor AE, Salit IE, Velland H (1984) The role ofMycobacterium xenopi in human disease. Am Rev Resp Dis 129:435–438

    PubMed  Google Scholar 

  22. Wise R, Griggs D, Andrews JM (1988) Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. Rev Infect Dis 10 (Suppl 1):S83-S89

    PubMed  Google Scholar 

  23. Wolinsky E (1979) Nontuberculous mycobacteria and associated diseases. Am Rev Resp Dis 119:107–159

    Google Scholar 

  24. Yajko DM, Nassos PS, Hadley WK (1987) Therapeutic implications of inhibition versus killing ofMycobacterium avium complex by antimicrobial agents. Antimicrob Agents Chemother 31:117–120

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Tuberculosis and Mycobacteriology Unit, Pasteur Institute, 25 Rue du Dr. Roux, F-75015, Paris, France

    Nalin Rastogi Dr.Sc., Marie-Christine Blom-Potar & Hugo L. David

Authors
  1. Nalin Rastogi Dr.Sc.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marie-Christine Blom-Potar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hugo L. David
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rastogi, N., Blom-Potar, MC. & David, H.L. Drug action against intracellularly growingMycobacterium xenopi . Current Microbiology 19, 83–89 (1989). https://doi.org/10.1007/BF01570573

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01570573

Keywords

Search

Navigation